nodes	percent_of_prediction	percent_of_DWPC	metapath
Terbinafine—PTGS1—Ifosfamide—testicular cancer	0.133	0.223	CbGbCtD
Terbinafine—CYP2C8—Ifosfamide—testicular cancer	0.0767	0.129	CbGbCtD
Terbinafine—CYP2C19—Ifosfamide—testicular cancer	0.0643	0.108	CbGbCtD
Terbinafine—PTGS1—Etoposide—testicular cancer	0.0635	0.106	CbGbCtD
Terbinafine—CYP2C9—Ifosfamide—testicular cancer	0.0535	0.0897	CbGbCtD
Terbinafine—CYP11A1—corpus luteum—testicular cancer	0.0415	0.238	CbGeAlD
Terbinafine—CYP2C8—Etoposide—testicular cancer	0.0366	0.0615	CbGbCtD
Terbinafine—CYP11A1—seminiferous tubule of testis—testicular cancer	0.0352	0.202	CbGeAlD
Terbinafine—CYP3A4—Ifosfamide—testicular cancer	0.0311	0.0521	CbGbCtD
Terbinafine—CYP1A2—Etoposide—testicular cancer	0.0284	0.0476	CbGbCtD
Terbinafine—CYP19A1—corpus luteum—testicular cancer	0.027	0.155	CbGeAlD
Terbinafine—CYP2C9—Cisplatin—testicular cancer	0.026	0.0436	CbGbCtD
Terbinafine—CYP2D6—Vinblastine—testicular cancer	0.0259	0.0435	CbGbCtD
Terbinafine—CYP19A1—seminiferous tubule of testis—testicular cancer	0.0229	0.131	CbGeAlD
Terbinafine—CYP3A4—Vinblastine—testicular cancer	0.0165	0.0277	CbGbCtD
Terbinafine—CYP2D6—Doxorubicin—testicular cancer	0.0159	0.0267	CbGbCtD
Terbinafine—CYP3A4—Etoposide—testicular cancer	0.0149	0.0249	CbGbCtD
Terbinafine—CYP19A1—semen—testicular cancer	0.0126	0.0725	CbGeAlD
Terbinafine—CYP3A4—Doxorubicin—testicular cancer	0.0101	0.017	CbGbCtD
Terbinafine—SQLE—gonad—testicular cancer	0.00455	0.0261	CbGeAlD
Terbinafine—SQLE—female gonad—testicular cancer	0.0037	0.0212	CbGeAlD
Terbinafine—SQLE—testis—testicular cancer	0.00328	0.0188	CbGeAlD
Terbinafine—CYP11A1—gonad—testicular cancer	0.00298	0.0171	CbGeAlD
Terbinafine—CYP11A1—female gonad—testicular cancer	0.00242	0.0139	CbGeAlD
Terbinafine—SQLE—lymph node—testicular cancer	0.00238	0.0136	CbGeAlD
Terbinafine—CYP11A1—testis—testicular cancer	0.00215	0.0123	CbGeAlD
Terbinafine—CYP19A1—gonad—testicular cancer	0.00194	0.0111	CbGeAlD
Terbinafine—CYP19A1—female gonad—testicular cancer	0.00157	0.00902	CbGeAlD
Terbinafine—CYP11A1—lymph node—testicular cancer	0.00156	0.00893	CbGeAlD
Terbinafine—PTGS1—seminal vesicle—testicular cancer	0.00156	0.00892	CbGeAlD
Terbinafine—CYP19A1—testis—testicular cancer	0.0014	0.008	CbGeAlD
Terbinafine—CYP19A1—lymph node—testicular cancer	0.00101	0.0058	CbGeAlD
Terbinafine—CYP2C8—testis—testicular cancer	0.000999	0.00573	CbGeAlD
Terbinafine—PTGS1—female gonad—testicular cancer	0.000914	0.00524	CbGeAlD
Terbinafine—PTGS1—testis—testicular cancer	0.00081	0.00465	CbGeAlD
Terbinafine—CYP2D6—female gonad—testicular cancer	0.000751	0.00431	CbGeAlD
Terbinafine—CYP2D6—testis—testicular cancer	0.000666	0.00382	CbGeAlD
Terbinafine—PTGS1—lymph node—testicular cancer	0.000587	0.00337	CbGeAlD
Terbinafine—Abdominal pain upper—Doxorubicin—testicular cancer	0.000299	0.0013	CcSEcCtD
Terbinafine—Photosensitivity reaction—Methotrexate—testicular cancer	0.000298	0.0013	CcSEcCtD
Terbinafine—Anorexia—Etoposide—testicular cancer	0.000296	0.00129	CcSEcCtD
Terbinafine—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	0.000295	0.00128	CcSEcCtD
Terbinafine—Decreased appetite—Cisplatin—testicular cancer	0.000294	0.00128	CcSEcCtD
Terbinafine—Diarrhoea—Dactinomycin—testicular cancer	0.000293	0.00128	CcSEcCtD
Terbinafine—Nasopharyngitis—Doxorubicin—testicular cancer	0.000293	0.00127	CcSEcCtD
Terbinafine—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000292	0.00127	CcSEcCtD
Terbinafine—Vomiting—Bleomycin—testicular cancer	0.000292	0.00127	CcSEcCtD
Terbinafine—Infestation NOS—Methotrexate—testicular cancer	0.000291	0.00127	CcSEcCtD
Terbinafine—Infestation—Methotrexate—testicular cancer	0.000291	0.00127	CcSEcCtD
Terbinafine—Pancytopenia—Epirubicin—testicular cancer	0.00029	0.00126	CcSEcCtD
Terbinafine—Rash—Bleomycin—testicular cancer	0.00029	0.00126	CcSEcCtD
Terbinafine—Gastritis—Doxorubicin—testicular cancer	0.00029	0.00126	CcSEcCtD
Terbinafine—Pain—Cisplatin—testicular cancer	0.000289	0.00126	CcSEcCtD
Terbinafine—Dermatitis—Bleomycin—testicular cancer	0.000289	0.00126	CcSEcCtD
Terbinafine—Hypersensitivity—Ifosfamide—testicular cancer	0.000289	0.00126	CcSEcCtD
Terbinafine—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.000289	0.00126	CcSEcCtD
Terbinafine—Neutropenia—Epirubicin—testicular cancer	0.000286	0.00125	CcSEcCtD
Terbinafine—Upper respiratory tract infection—Epirubicin—testicular cancer	0.000284	0.00124	CcSEcCtD
Terbinafine—Influenza—Doxorubicin—testicular cancer	0.000283	0.00123	CcSEcCtD
Terbinafine—Asthenia—Ifosfamide—testicular cancer	0.000282	0.00123	CcSEcCtD
Terbinafine—Eosinophilia—Doxorubicin—testicular cancer	0.00028	0.00122	CcSEcCtD
Terbinafine—Photosensitivity reaction—Epirubicin—testicular cancer	0.000279	0.00122	CcSEcCtD
Terbinafine—Feeling abnormal—Cisplatin—testicular cancer	0.000279	0.00122	CcSEcCtD
Terbinafine—Paraesthesia—Etoposide—testicular cancer	0.000278	0.00121	CcSEcCtD
Terbinafine—Pruritus—Ifosfamide—testicular cancer	0.000278	0.00121	CcSEcCtD
Terbinafine—Pancreatitis—Doxorubicin—testicular cancer	0.000277	0.00121	CcSEcCtD
Terbinafine—Weight decreased—Epirubicin—testicular cancer	0.000276	0.0012	CcSEcCtD
Terbinafine—Hepatobiliary disease—Methotrexate—testicular cancer	0.000275	0.0012	CcSEcCtD
Terbinafine—Nausea—Bleomycin—testicular cancer	0.000273	0.00119	CcSEcCtD
Terbinafine—Infestation NOS—Epirubicin—testicular cancer	0.000272	0.00119	CcSEcCtD
Terbinafine—Infestation—Epirubicin—testicular cancer	0.000272	0.00119	CcSEcCtD
Terbinafine—Vomiting—Dactinomycin—testicular cancer	0.000272	0.00119	CcSEcCtD
Terbinafine—Agranulocytosis—Methotrexate—testicular cancer	0.000272	0.00118	CcSEcCtD
Terbinafine—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.00027	0.00118	CcSEcCtD
Terbinafine—Rash—Dactinomycin—testicular cancer	0.00027	0.00118	CcSEcCtD
Terbinafine—Decreased appetite—Etoposide—testicular cancer	0.000269	0.00117	CcSEcCtD
Terbinafine—Diarrhoea—Ifosfamide—testicular cancer	0.000269	0.00117	CcSEcCtD
Terbinafine—Pancytopenia—Doxorubicin—testicular cancer	0.000269	0.00117	CcSEcCtD
Terbinafine—Gastrointestinal disorder—Etoposide—testicular cancer	0.000268	0.00117	CcSEcCtD
Terbinafine—Body temperature increased—Cisplatin—testicular cancer	0.000268	0.00117	CcSEcCtD
Terbinafine—Fatigue—Etoposide—testicular cancer	0.000267	0.00116	CcSEcCtD
Terbinafine—Jaundice—Epirubicin—testicular cancer	0.000266	0.00116	CcSEcCtD
Terbinafine—Pain—Etoposide—testicular cancer	0.000265	0.00116	CcSEcCtD
Terbinafine—Neutropenia—Doxorubicin—testicular cancer	0.000264	0.00115	CcSEcCtD
Terbinafine—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.000263	0.00115	CcSEcCtD
Terbinafine—Hepatitis—Methotrexate—testicular cancer	0.000261	0.00114	CcSEcCtD
Terbinafine—Dizziness—Ifosfamide—testicular cancer	0.00026	0.00113	CcSEcCtD
Terbinafine—Photosensitivity reaction—Doxorubicin—testicular cancer	0.000258	0.00112	CcSEcCtD
Terbinafine—Hepatobiliary disease—Epirubicin—testicular cancer	0.000258	0.00112	CcSEcCtD
Terbinafine—Weight decreased—Doxorubicin—testicular cancer	0.000256	0.00111	CcSEcCtD
Terbinafine—Feeling abnormal—Etoposide—testicular cancer	0.000255	0.00111	CcSEcCtD
Terbinafine—Nausea—Dactinomycin—testicular cancer	0.000254	0.00111	CcSEcCtD
Terbinafine—Agranulocytosis—Epirubicin—testicular cancer	0.000254	0.00111	CcSEcCtD
Terbinafine—Gastrointestinal pain—Etoposide—testicular cancer	0.000254	0.0011	CcSEcCtD
Terbinafine—Infestation NOS—Doxorubicin—testicular cancer	0.000252	0.0011	CcSEcCtD
Terbinafine—Infestation—Doxorubicin—testicular cancer	0.000252	0.0011	CcSEcCtD
Terbinafine—Visual impairment—Methotrexate—testicular cancer	0.000252	0.0011	CcSEcCtD
Terbinafine—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.00025	0.00109	CcSEcCtD
Terbinafine—Vomiting—Ifosfamide—testicular cancer	0.00025	0.00109	CcSEcCtD
Terbinafine—Hypersensitivity—Cisplatin—testicular cancer	0.000249	0.00109	CcSEcCtD
Terbinafine—Rash—Ifosfamide—testicular cancer	0.000247	0.00108	CcSEcCtD
Terbinafine—Dermatitis—Ifosfamide—testicular cancer	0.000247	0.00108	CcSEcCtD
Terbinafine—Erythema multiforme—Methotrexate—testicular cancer	0.000247	0.00108	CcSEcCtD
Terbinafine—Urticaria—Etoposide—testicular cancer	0.000246	0.00107	CcSEcCtD
Terbinafine—Jaundice—Doxorubicin—testicular cancer	0.000246	0.00107	CcSEcCtD
Terbinafine—Abdominal pain—Etoposide—testicular cancer	0.000245	0.00107	CcSEcCtD
Terbinafine—Body temperature increased—Etoposide—testicular cancer	0.000245	0.00107	CcSEcCtD
Terbinafine—Hepatitis—Epirubicin—testicular cancer	0.000245	0.00107	CcSEcCtD
Terbinafine—Eye disorder—Methotrexate—testicular cancer	0.000244	0.00106	CcSEcCtD
Terbinafine—Tinnitus—Methotrexate—testicular cancer	0.000244	0.00106	CcSEcCtD
Terbinafine—Hypoaesthesia—Epirubicin—testicular cancer	0.000243	0.00106	CcSEcCtD
Terbinafine—Asthenia—Cisplatin—testicular cancer	0.000243	0.00106	CcSEcCtD
Terbinafine—Connective tissue disorder—Epirubicin—testicular cancer	0.00024	0.00105	CcSEcCtD
Terbinafine—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000238	0.00104	CcSEcCtD
Terbinafine—Angiopathy—Methotrexate—testicular cancer	0.000237	0.00103	CcSEcCtD
Terbinafine—Immune system disorder—Methotrexate—testicular cancer	0.000236	0.00103	CcSEcCtD
Terbinafine—Visual impairment—Epirubicin—testicular cancer	0.000236	0.00103	CcSEcCtD
Terbinafine—Agranulocytosis—Doxorubicin—testicular cancer	0.000235	0.00103	CcSEcCtD
Terbinafine—Nausea—Ifosfamide—testicular cancer	0.000233	0.00102	CcSEcCtD
Terbinafine—Diarrhoea—Cisplatin—testicular cancer	0.000232	0.00101	CcSEcCtD
Terbinafine—Erythema multiforme—Epirubicin—testicular cancer	0.000231	0.00101	CcSEcCtD
Terbinafine—Alopecia—Methotrexate—testicular cancer	0.000231	0.00101	CcSEcCtD
Terbinafine—Mental disorder—Methotrexate—testicular cancer	0.000229	0.000998	CcSEcCtD
Terbinafine—Eye disorder—Epirubicin—testicular cancer	0.000229	0.000996	CcSEcCtD
Terbinafine—Hypersensitivity—Etoposide—testicular cancer	0.000228	0.000995	CcSEcCtD
Terbinafine—Tinnitus—Epirubicin—testicular cancer	0.000228	0.000994	CcSEcCtD
Terbinafine—Erythema—Methotrexate—testicular cancer	0.000228	0.000992	CcSEcCtD
Terbinafine—Hepatitis—Doxorubicin—testicular cancer	0.000226	0.000986	CcSEcCtD
Terbinafine—Hypoaesthesia—Doxorubicin—testicular cancer	0.000225	0.000981	CcSEcCtD
Terbinafine—Dysgeusia—Methotrexate—testicular cancer	0.000223	0.000971	CcSEcCtD
Terbinafine—Asthenia—Etoposide—testicular cancer	0.000222	0.000969	CcSEcCtD
Terbinafine—Connective tissue disorder—Doxorubicin—testicular cancer	0.000222	0.000969	CcSEcCtD
Terbinafine—Angiopathy—Epirubicin—testicular cancer	0.000222	0.000967	CcSEcCtD
Terbinafine—Immune system disorder—Epirubicin—testicular cancer	0.000221	0.000963	CcSEcCtD
Terbinafine—Pruritus—Etoposide—testicular cancer	0.000219	0.000956	CcSEcCtD
Terbinafine—Visual impairment—Doxorubicin—testicular cancer	0.000218	0.00095	CcSEcCtD
Terbinafine—Alopecia—Epirubicin—testicular cancer	0.000216	0.000942	CcSEcCtD
Terbinafine—Vomiting—Cisplatin—testicular cancer	0.000215	0.000938	CcSEcCtD
Terbinafine—Vision blurred—Methotrexate—testicular cancer	0.000214	0.000934	CcSEcCtD
Terbinafine—Mental disorder—Epirubicin—testicular cancer	0.000214	0.000934	CcSEcCtD
Terbinafine—Erythema multiforme—Doxorubicin—testicular cancer	0.000214	0.000933	CcSEcCtD
Terbinafine—Rash—Cisplatin—testicular cancer	0.000213	0.00093	CcSEcCtD
Terbinafine—Dermatitis—Cisplatin—testicular cancer	0.000213	0.000929	CcSEcCtD
Terbinafine—Erythema—Epirubicin—testicular cancer	0.000213	0.000928	CcSEcCtD
Terbinafine—Diarrhoea—Etoposide—testicular cancer	0.000212	0.000924	CcSEcCtD
Terbinafine—Eye disorder—Doxorubicin—testicular cancer	0.000212	0.000922	CcSEcCtD
Terbinafine—Ill-defined disorder—Methotrexate—testicular cancer	0.000211	0.00092	CcSEcCtD
Terbinafine—Tinnitus—Doxorubicin—testicular cancer	0.000211	0.00092	CcSEcCtD
Terbinafine—Anaemia—Methotrexate—testicular cancer	0.00021	0.000916	CcSEcCtD
Terbinafine—Flatulence—Epirubicin—testicular cancer	0.00021	0.000914	CcSEcCtD
Terbinafine—Dysgeusia—Epirubicin—testicular cancer	0.000209	0.000909	CcSEcCtD
Terbinafine—Angiopathy—Doxorubicin—testicular cancer	0.000205	0.000895	CcSEcCtD
Terbinafine—Malaise—Methotrexate—testicular cancer	0.000205	0.000894	CcSEcCtD
Terbinafine—Dizziness—Etoposide—testicular cancer	0.000205	0.000893	CcSEcCtD
Terbinafine—Muscle spasms—Epirubicin—testicular cancer	0.000205	0.000892	CcSEcCtD
Terbinafine—Immune system disorder—Doxorubicin—testicular cancer	0.000204	0.000891	CcSEcCtD
Terbinafine—Vertigo—Methotrexate—testicular cancer	0.000204	0.000891	CcSEcCtD
Terbinafine—Nausea—Cisplatin—testicular cancer	0.000201	0.000876	CcSEcCtD
Terbinafine—Vision blurred—Epirubicin—testicular cancer	0.000201	0.000875	CcSEcCtD
Terbinafine—Alopecia—Doxorubicin—testicular cancer	0.0002	0.000872	CcSEcCtD
Terbinafine—Cough—Methotrexate—testicular cancer	0.000199	0.000865	CcSEcCtD
Terbinafine—Mental disorder—Doxorubicin—testicular cancer	0.000198	0.000864	CcSEcCtD
Terbinafine—Ill-defined disorder—Epirubicin—testicular cancer	0.000198	0.000861	CcSEcCtD
Terbinafine—Vomiting—Etoposide—testicular cancer	0.000197	0.000859	CcSEcCtD
Terbinafine—Erythema—Doxorubicin—testicular cancer	0.000197	0.000859	CcSEcCtD
Terbinafine—Anaemia—Epirubicin—testicular cancer	0.000197	0.000858	CcSEcCtD
Terbinafine—Rash—Etoposide—testicular cancer	0.000195	0.000852	CcSEcCtD
Terbinafine—Dermatitis—Etoposide—testicular cancer	0.000195	0.000851	CcSEcCtD
Terbinafine—Headache—Etoposide—testicular cancer	0.000194	0.000846	CcSEcCtD
Terbinafine—Flatulence—Doxorubicin—testicular cancer	0.000194	0.000846	CcSEcCtD
Terbinafine—Arthralgia—Methotrexate—testicular cancer	0.000194	0.000844	CcSEcCtD
Terbinafine—Chest pain—Methotrexate—testicular cancer	0.000194	0.000844	CcSEcCtD
Terbinafine—Myalgia—Methotrexate—testicular cancer	0.000194	0.000844	CcSEcCtD
Terbinafine—Dysgeusia—Doxorubicin—testicular cancer	0.000193	0.000841	CcSEcCtD
Terbinafine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000192	0.000838	CcSEcCtD
Terbinafine—Malaise—Epirubicin—testicular cancer	0.000192	0.000837	CcSEcCtD
Terbinafine—Discomfort—Methotrexate—testicular cancer	0.000191	0.000834	CcSEcCtD
Terbinafine—Vertigo—Epirubicin—testicular cancer	0.000191	0.000834	CcSEcCtD
Terbinafine—Muscle spasms—Doxorubicin—testicular cancer	0.000189	0.000825	CcSEcCtD
Terbinafine—Confusional state—Methotrexate—testicular cancer	0.000187	0.000816	CcSEcCtD
Terbinafine—Cough—Epirubicin—testicular cancer	0.000186	0.00081	CcSEcCtD
Terbinafine—Anaphylactic shock—Methotrexate—testicular cancer	0.000186	0.000809	CcSEcCtD
Terbinafine—Vision blurred—Doxorubicin—testicular cancer	0.000186	0.000809	CcSEcCtD
Terbinafine—Infection—Methotrexate—testicular cancer	0.000184	0.000804	CcSEcCtD
Terbinafine—Nausea—Etoposide—testicular cancer	0.000184	0.000802	CcSEcCtD
Terbinafine—Ill-defined disorder—Doxorubicin—testicular cancer	0.000183	0.000797	CcSEcCtD
Terbinafine—Nervous system disorder—Methotrexate—testicular cancer	0.000182	0.000794	CcSEcCtD
Terbinafine—Anaemia—Doxorubicin—testicular cancer	0.000182	0.000794	CcSEcCtD
Terbinafine—Thrombocytopenia—Methotrexate—testicular cancer	0.000182	0.000792	CcSEcCtD
Terbinafine—Chest pain—Epirubicin—testicular cancer	0.000181	0.00079	CcSEcCtD
Terbinafine—Myalgia—Epirubicin—testicular cancer	0.000181	0.00079	CcSEcCtD
Terbinafine—Arthralgia—Epirubicin—testicular cancer	0.000181	0.00079	CcSEcCtD
Terbinafine—Anxiety—Epirubicin—testicular cancer	0.000181	0.000787	CcSEcCtD
Terbinafine—Skin disorder—Methotrexate—testicular cancer	0.00018	0.000786	CcSEcCtD
Terbinafine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.00018	0.000785	CcSEcCtD
Terbinafine—Discomfort—Epirubicin—testicular cancer	0.000179	0.000781	CcSEcCtD
Terbinafine—Malaise—Doxorubicin—testicular cancer	0.000178	0.000774	CcSEcCtD
Terbinafine—Dry mouth—Epirubicin—testicular cancer	0.000177	0.000773	CcSEcCtD
Terbinafine—Vertigo—Doxorubicin—testicular cancer	0.000177	0.000771	CcSEcCtD
Terbinafine—Anorexia—Methotrexate—testicular cancer	0.000177	0.000771	CcSEcCtD
Terbinafine—Confusional state—Epirubicin—testicular cancer	0.000175	0.000764	CcSEcCtD
Terbinafine—Anaphylactic shock—Epirubicin—testicular cancer	0.000174	0.000757	CcSEcCtD
Terbinafine—Infection—Epirubicin—testicular cancer	0.000173	0.000752	CcSEcCtD
Terbinafine—Cough—Doxorubicin—testicular cancer	0.000172	0.000749	CcSEcCtD
Terbinafine—Nervous system disorder—Epirubicin—testicular cancer	0.00017	0.000743	CcSEcCtD
Terbinafine—Thrombocytopenia—Epirubicin—testicular cancer	0.00017	0.000741	CcSEcCtD
Terbinafine—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000169	0.000737	CcSEcCtD
Terbinafine—Skin disorder—Epirubicin—testicular cancer	0.000169	0.000736	CcSEcCtD
Terbinafine—Chest pain—Doxorubicin—testicular cancer	0.000168	0.000731	CcSEcCtD
Terbinafine—Myalgia—Doxorubicin—testicular cancer	0.000168	0.000731	CcSEcCtD
Terbinafine—Arthralgia—Doxorubicin—testicular cancer	0.000168	0.000731	CcSEcCtD
Terbinafine—Anxiety—Doxorubicin—testicular cancer	0.000167	0.000728	CcSEcCtD
Terbinafine—Paraesthesia—Methotrexate—testicular cancer	0.000167	0.000727	CcSEcCtD
Terbinafine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000167	0.000726	CcSEcCtD
Terbinafine—Discomfort—Doxorubicin—testicular cancer	0.000166	0.000722	CcSEcCtD
Terbinafine—Anorexia—Epirubicin—testicular cancer	0.000166	0.000722	CcSEcCtD
Terbinafine—Dry mouth—Doxorubicin—testicular cancer	0.000164	0.000715	CcSEcCtD
Terbinafine—Dyspepsia—Methotrexate—testicular cancer	0.000163	0.000712	CcSEcCtD
Terbinafine—Confusional state—Doxorubicin—testicular cancer	0.000162	0.000707	CcSEcCtD
Terbinafine—Decreased appetite—Methotrexate—testicular cancer	0.000161	0.000703	CcSEcCtD
Terbinafine—Anaphylactic shock—Doxorubicin—testicular cancer	0.000161	0.000701	CcSEcCtD
Terbinafine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.00016	0.000699	CcSEcCtD
Terbinafine—Fatigue—Methotrexate—testicular cancer	0.00016	0.000698	CcSEcCtD
Terbinafine—Infection—Doxorubicin—testicular cancer	0.00016	0.000696	CcSEcCtD
Terbinafine—Pain—Methotrexate—testicular cancer	0.000159	0.000692	CcSEcCtD
Terbinafine—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000158	0.00069	CcSEcCtD
Terbinafine—Nervous system disorder—Doxorubicin—testicular cancer	0.000158	0.000687	CcSEcCtD
Terbinafine—Thrombocytopenia—Doxorubicin—testicular cancer	0.000157	0.000686	CcSEcCtD
Terbinafine—Skin disorder—Doxorubicin—testicular cancer	0.000156	0.000681	CcSEcCtD
Terbinafine—Paraesthesia—Epirubicin—testicular cancer	0.000156	0.00068	CcSEcCtD
Terbinafine—Anorexia—Doxorubicin—testicular cancer	0.000153	0.000668	CcSEcCtD
Terbinafine—Feeling abnormal—Methotrexate—testicular cancer	0.000153	0.000667	CcSEcCtD
Terbinafine—Dyspepsia—Epirubicin—testicular cancer	0.000153	0.000667	CcSEcCtD
Terbinafine—Gastrointestinal pain—Methotrexate—testicular cancer	0.000152	0.000662	CcSEcCtD
Terbinafine—Decreased appetite—Epirubicin—testicular cancer	0.000151	0.000658	CcSEcCtD
Terbinafine—Gastrointestinal disorder—Epirubicin—testicular cancer	0.00015	0.000654	CcSEcCtD
Terbinafine—Fatigue—Epirubicin—testicular cancer	0.00015	0.000653	CcSEcCtD
Terbinafine—Pain—Epirubicin—testicular cancer	0.000149	0.000648	CcSEcCtD
Terbinafine—Urticaria—Methotrexate—testicular cancer	0.000148	0.000643	CcSEcCtD
Terbinafine—Abdominal pain—Methotrexate—testicular cancer	0.000147	0.00064	CcSEcCtD
Terbinafine—Body temperature increased—Methotrexate—testicular cancer	0.000147	0.00064	CcSEcCtD
Terbinafine—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000146	0.000638	CcSEcCtD
Terbinafine—Paraesthesia—Doxorubicin—testicular cancer	0.000144	0.000629	CcSEcCtD
Terbinafine—Feeling abnormal—Epirubicin—testicular cancer	0.000143	0.000624	CcSEcCtD
Terbinafine—Gastrointestinal pain—Epirubicin—testicular cancer	0.000142	0.000619	CcSEcCtD
Terbinafine—Dyspepsia—Doxorubicin—testicular cancer	0.000142	0.000617	CcSEcCtD
Terbinafine—Decreased appetite—Doxorubicin—testicular cancer	0.00014	0.000609	CcSEcCtD
Terbinafine—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000139	0.000605	CcSEcCtD
Terbinafine—Fatigue—Doxorubicin—testicular cancer	0.000139	0.000604	CcSEcCtD
Terbinafine—Urticaria—Epirubicin—testicular cancer	0.000138	0.000602	CcSEcCtD
Terbinafine—Pain—Doxorubicin—testicular cancer	0.000138	0.000599	CcSEcCtD
Terbinafine—Abdominal pain—Epirubicin—testicular cancer	0.000137	0.000599	CcSEcCtD
Terbinafine—Body temperature increased—Epirubicin—testicular cancer	0.000137	0.000599	CcSEcCtD
Terbinafine—Hypersensitivity—Methotrexate—testicular cancer	0.000137	0.000596	CcSEcCtD
Terbinafine—Asthenia—Methotrexate—testicular cancer	0.000133	0.000581	CcSEcCtD
Terbinafine—Feeling abnormal—Doxorubicin—testicular cancer	0.000133	0.000577	CcSEcCtD
Terbinafine—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000131	0.000573	CcSEcCtD
Terbinafine—Pruritus—Methotrexate—testicular cancer	0.000131	0.000573	CcSEcCtD
Terbinafine—Hypersensitivity—Epirubicin—testicular cancer	0.000128	0.000558	CcSEcCtD
Terbinafine—Urticaria—Doxorubicin—testicular cancer	0.000128	0.000557	CcSEcCtD
Terbinafine—Abdominal pain—Doxorubicin—testicular cancer	0.000127	0.000554	CcSEcCtD
Terbinafine—Body temperature increased—Doxorubicin—testicular cancer	0.000127	0.000554	CcSEcCtD
Terbinafine—Diarrhoea—Methotrexate—testicular cancer	0.000127	0.000554	CcSEcCtD
Terbinafine—Asthenia—Epirubicin—testicular cancer	0.000125	0.000543	CcSEcCtD
Terbinafine—Pruritus—Epirubicin—testicular cancer	0.000123	0.000536	CcSEcCtD
Terbinafine—Dizziness—Methotrexate—testicular cancer	0.000123	0.000535	CcSEcCtD
Terbinafine—Diarrhoea—Epirubicin—testicular cancer	0.000119	0.000518	CcSEcCtD
Terbinafine—Hypersensitivity—Doxorubicin—testicular cancer	0.000118	0.000516	CcSEcCtD
Terbinafine—Vomiting—Methotrexate—testicular cancer	0.000118	0.000515	CcSEcCtD
Terbinafine—Rash—Methotrexate—testicular cancer	0.000117	0.00051	CcSEcCtD
Terbinafine—Dermatitis—Methotrexate—testicular cancer	0.000117	0.00051	CcSEcCtD
Terbinafine—Headache—Methotrexate—testicular cancer	0.000116	0.000507	CcSEcCtD
Terbinafine—Asthenia—Doxorubicin—testicular cancer	0.000115	0.000503	CcSEcCtD
Terbinafine—Dizziness—Epirubicin—testicular cancer	0.000115	0.000501	CcSEcCtD
Terbinafine—Pruritus—Doxorubicin—testicular cancer	0.000114	0.000496	CcSEcCtD
Terbinafine—Vomiting—Epirubicin—testicular cancer	0.00011	0.000482	CcSEcCtD
Terbinafine—Nausea—Methotrexate—testicular cancer	0.00011	0.000481	CcSEcCtD
Terbinafine—Diarrhoea—Doxorubicin—testicular cancer	0.00011	0.000479	CcSEcCtD
Terbinafine—Rash—Epirubicin—testicular cancer	0.00011	0.000477	CcSEcCtD
Terbinafine—Dermatitis—Epirubicin—testicular cancer	0.000109	0.000477	CcSEcCtD
Terbinafine—Headache—Epirubicin—testicular cancer	0.000109	0.000474	CcSEcCtD
Terbinafine—Dizziness—Doxorubicin—testicular cancer	0.000106	0.000463	CcSEcCtD
Terbinafine—Nausea—Epirubicin—testicular cancer	0.000103	0.00045	CcSEcCtD
Terbinafine—Vomiting—Doxorubicin—testicular cancer	0.000102	0.000446	CcSEcCtD
Terbinafine—Rash—Doxorubicin—testicular cancer	0.000101	0.000442	CcSEcCtD
Terbinafine—Dermatitis—Doxorubicin—testicular cancer	0.000101	0.000441	CcSEcCtD
Terbinafine—Headache—Doxorubicin—testicular cancer	0.000101	0.000439	CcSEcCtD
Terbinafine—Nausea—Doxorubicin—testicular cancer	9.55e-05	0.000416	CcSEcCtD
